IRCT20200105046010N72招募中未知
In- Vivo Bioequivalence study of Atorvastatin tablets 40 mg Kharazmi Pharma with brand drugs (LIPITOR® 40 mg, Pfizer, Germany) in Iranian healthy volunteers.
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General health
- •Body mass index between18-28
- •Informed consent
- •Being at the age of 18-55 years old
排除标准
- •A history of cardiovascular disease
- •A history of liver & kidney disease
- •Alcohol & Drug addiction
- •Hypersensitivity to the drug
研究者
相似试验
招募中
不适用
In-vivo Bioequivalence Test of Atorvastatin® tablet with brand drugs (LIPITOR® 100mg, Pfizer, Germany).IRCT20200105046010N33Razak Pharma24
招募中
不适用
In-vivo Bioequivalence Test of Atorvastatin® tablet with brand drugs (LIPITOR® 100mg, Pfizer, Germany).IRCT20200105046010N29Zagross Darou Pharmaceutical Company24
尚未招募
不适用
Study of absorption and elimination rate of Atorvastatin 80-mg/Ezetimibe 10-mg tablet (Lipzib®) in comparison with Atorvastatin 80-mg/Ezetimibe 10-mg brand tablet (Liptruzit®)IRCT20200407046981N34ikasa Pharmed Pharmaceutical Company24
招募中
不适用
In-vivo Bioequivalence Test of Rosuvastatin tablets with brand drug (CRESTOR® 20mg F.C Tab, AstraZeneca, Belgium)IRCT20200105046010N41Kharazmi Pharmaceutical Co24
尚未招募
4 期
Bioequivalence Study of 80 mg Atorvastatin in healthy Thai volunteers under fasting conditioRecently,Company has manufactured a new formulation of atorvastatin tablets 80 mg for which this study has been planned to evaluate the pharmacokinetics of the new formulationTCTR20161109001Research and Development36